Keywords: Bayer, Xarelto, Johnson & Johnson, Bristol-Myers, Pfizer, Eliquis, Coronary syndrome, VTE

Bayer’s Xarelto significantly reduced mortality in major ACS study; Bristol-Myers’ Eliquis fails endpoint in VTE trial

Article | 14 November 2011

Print This

The US unit of Germany’s Bayer (BAY: DE) yesterday announced that the combination of oral Xarelto (rivaroxaban) twice ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in